(Q34502083)

2 August 2017

1 reference

title

Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia (English)

1 reference

2 August 2017

0 references

cognitive dysfunction

1 reference

Neelam Thakurathi

1

1 reference

2 August 2017

Brenda Vincenzi

series ordinal

2

1 reference

2 August 2017

David C Henderson

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

9 December 2012

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

published in

1 reference

2 August 2017

volume

22

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

259-265

1 reference

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

The CATIE schizophrenia trial: results, impact, controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Baseline neurocognitive deficits in the CATIE schizophrenia trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Dopamine in schizophrenia: a review and reconceptualization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Cholinergic enhancement and increased selectivity of perceptual processing during working memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

21 January 2018

Acetylcholine and memory

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Nicotine-haloperidol interactions and cognitive performance in schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Cholinergic strategies for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

The effect of galantamine added to clozapine on cognition of five patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Galantamine for the treatment of cognitive impairments in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

Prevalence of smoking among psychiatric outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.750650

10.1517/13543784.2013.750650

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference